Endophthalmitis: Pathogenesis, clinical presentation, management, and perspectives

Clinical Ophthalmology

Volumn 4, Issue 1, 2010, Pages 121-135

  Kernt, M ^a   Kampik, A ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antibiotics; Caspofungin; Endophthalmitis; Intravitreal; Moxifloxacin; Victrectomy; Voriconazole

Indexed keywords

AMIKACIN; AMPHOTERICIN B; CASPOFUNGIN; CEFTAZIDIME; CEFUROXIME; CORTICOSTEROID; DEXAMETHASONE; FLUCONAZOLE; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STEROID; TRIAMCINOLONE ACETONIDE; TRIAZOLE; VANCOMYCIN; VORICONAZOLE;

ADJUVANT THERAPY; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; BACTERIAL INFECTION; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BACTERIUM ADHERENCE; CLINICAL FEATURE; CLINICAL TRIAL; DRUG MECHANISM; DRUG TISSUE LEVEL; DRUG TREATMENT FAILURE; EARLY INTERVENTION; ENDOPHTHALMITIS; EYE INJURY; EYE SURGERY; EYE TOXICITY; FUNGAL ENDOPHTHALMITIS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; HYPOPYON; INFECTION PREVENTION; INFECTION RISK; LENS IMPLANT; NONHUMAN; PATHOGENESIS; POSTOPERATIVE INFECTION; POSTTRAUMATIC COMPLICATION; PROSTHESIS MATERIAL; RETINA DISEASE; REVIEW; VITRECTOMY;

EID: 77953460085     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/opth.s6461     Document Type: Review

References (172)

1. Mamalis N. Endophthalmitis. J Cataract Refract Surg. 2002;28(5): 729-730.
2. Essman TF, Flynn HW Jr, Smiddy WE, et al. Treatment outcomes in a 10-year study of endogenous fungal endophthalmitis. Ophthalmic Surg Lasers. 1997;28(3):185-194.
3. Jackson TL, Eykyn SJ, Graham EM, Stanford MR. Endogenous bac-terial endophthalmitis: 17-year prospective series and review of 267 reported cases. Surg Ophthalmol. 2003;48(4):403-423.
4. Okada AA, Johnson RP, Liles WC, D'Amico DJ, Baker AS. Endog-enous bacterial endophthalmitis. Report of a ten-year retrospective study. Ophthalmology. 1994;101(5):832-838.
5. Rao NA, Hidayat AA. Endogenous mycotic endophthalmitis: Variations in clinical and histopathologic changes in candidiasis compared with aspergillosis. Am J Ophthalmol. 2001;132(2):244-251.
6. Tanaka M, Kobayashi Y, Takebayashi H, Kiyokawa M, Qiu H. Analysis of predisposing clinical and laboratory findings for the development of endogenous fungal endophthalmitis. A retrospective 12-year study of 79 eyes of 46 patients. Retina. 2001;21(3):203-209.
7. Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Endophthalmitis Vitrectomy Study Group. Arch Ophthalmol. 1995;113(12):1479-1496.
8. Essex RW, Yi Q, Charles PG, Allen PJ. Post-traumatic endophthalmitis. Ophthalmology. 2004;111(11):2015-2022.
9. Kattan HM, Flynn HW Jr, Pflugfelder SC, Robertson C, Forster RK. Nosocomial endophthalmitis survey. Current incidence of infection after intraocular surgery. Ophthalmology. 1991;98(2):227-238.
10. Aaberg TM Jr, Flynn HW Jr, Schiffman J, Newton J. Nosocomial acute-onset postoperative endophthalmitis survey. A 10-year review of incidence and outcomes. Ophthalmology. 1998;105(6):1004-1010.
11. Bainbridge JW, Teimory M, Tabandeh H, et al. Intraocular lens implants and risk of endophthalmitis. Br J Ophthalmol. 1998;82(11): 1312-1315.
12. Javitt JC, Street DA, Tielsch JM, et al. National outcomes of cataract extraction. Retinal detachment and endophthalmitis after outpatient cataract surgery. Cataract Patient Outcomes Research Team. Ophthalmology. 1994;101(1):100-105; discussion 106.
13. Mamalis N, Nagpal M, Nagpal K, Nagpal PN. Endophthalmitis following cataract surgery. Ophthalmol Clin North Am. 2001;14(4): 661-674, ix.
14. Morlet N, Gatus B, Coroneo M. Patterns of peri-operative prophylaxis for cataract surgery: A survey of Australian ophthalmologists. Aust N Z J Ophthalmol. 1998;26(1):5-12.
15. Morlet N, Li J, Semmens J, Ng J. The Endophthalmitis Population Study of Western Australia (EPSWA): First report. Br J Ophthalmol. 2003;87(5):574-576.
16. Taban M, Behrens A, Newcomb RL, et al. Acute endophthalmitis following cataract surgery: A systematic review of the literature. Arch Ophthalmol. 2005;123(5):613-620.
17. Cooper BA, Holekamp NM, Bohigian G, Thompson PA. Case-control study of endophthalmitis after cataract surgery comparing scleral tunnel and clear corneal wounds. Am J Ophthalmol. 2003;136(2): 300-305.
18. Nagaki Y, Hayasaka S, Kadoi C, et al. Bacterial endophthalmitis after small-incision cataract surgery. Effect of incision placement and intra-ocular lens type. J Cataract Refract Surg. 2003;29(1):20-26.
19. Lalwani GA, Flynn HW Jr, et al. Acute-onset endophthalmitis after clear corneal cataract surgery (1996-2005). Clinical features, causative organisms, and visual acuity outcomes. Ophthalmology. 2008;115(3):473-476.
20. Eifrig CW, Flynn HW Jr, Scott IU, Newton J. Acute-onset postoperative endophthalmitis: Review of incidence and visual outcomes (1995-2001). Ophthalmic Surg Lasers. 2002;33(5):373-378.
21. Scott IU, Flynn HW Jr, Dev S, Shaikh S, Mittra RA, Arevalo JF, et al. Endophthalmitis after 25-gauge and 20-gauge pars plana vitrectomy: Incidence and outcomes. Retina. 2008;28(1):138-142.
22. Cantrill HL, Henry K, Melroe NH, Knobloch WH, Ramsay RC, Balfour HH Jr. Treatment of cytomegalovirus retinitis with intra-vitreal ganciclovir. Long-term results. Ophthalmology. 1989; 96(3): 367-374.
23. Jager RD, Aiello LP, Patel SC, Cunningham ET Jr. Risks of intravitre-ous injection: A comprehensive review. Retina. 2004;24(5):676-698.
24. Ciulla TA, Baker AS. Endophthalmitis following glaucoma filtering surgery. Int Ophthalmol Clin. 1996;36(3):87-96.
25. Al-Torbak AA, Al-Shahwan S, Al-Jadaan I, Al-Hommadi A, Edward DP. Endophthalmitis associated with the Ahmed glaucoma valve implant. Br J Ophthalmol. 2005;89(4):454-458.
26. Hassan SS, Wilhelmus KR, Dahl P, Davis GC, Roberts RT, Ross KW, et al. Infectious disease risk factors of corneal graft donors. Arch Oph-thalmol. 2008;126(2):235-239.
27. Muckley ED, Lehrer RA. Late-onset blebitis/endophthalmitis: Incidence and outcomes with mitomycin C. Optom Vis Sci. 2004;81(7): 499-504.
28. Sharan S, Trope GE, Chipman M, Buys YM. Late-onset bleb infections: Prevalence and risk factors. Can J Ophthalmol. 2009;44(3):279-283.
29. Greenfield DS, Suner IJ, Miller MP, Kangas TA, Palmberg PF, Flynn HW Jr. Endophthalmitis after filtering surgery with mitomycin. Arch Ophthalmol. 1996;114(8):943-949.
30. Kangas TA, Greenfield DS, Flynn HW Jr, Parrish RK 2nd, Palmberg P. Delayed-onset endophthalmitis associated with conjunctival filtering blebs. Ophthalmology. 1997;104(5):746-752.
31. Song A, Scott IU, Flynn HW Jr, Budenz DL. Delayed-onset bleb-associated endophthalmitis: Clinical features and visual acuity out-comes. Ophthalmology. 2002;109(5):985-991.
32. Wolner B, Liebmann JM, Sassani JW, Ritch R, Speaker M, Marmor M. Late bleb-related endophthalmitis after trabeculectomy with adjunctive 5-fluorouracil. Ophthalmology. 1991;98(7):1053-1060.
33. Higginbotham EJ, Stevens RK, Musch DC, Karp KO, Lichter PR, Bergstrom TJ, et al. Bleb-related endophthalmitis after trabeculectomy with mitomycin C. Ophthalmology. 1996;103(4):650-656.
34. Peponis V, Rosenberg P, Chalkiadakis SE, Insler M, Amariotakis A. Fungal scleral keratitis and endophthalmitis following pterygium exci-sion. Eur J Ophthalmol. 2009;19(3):478-480.
35. Khurshid GS, Fahy GT. Endophthalmitis secondary to corneal sutures: Series of delayed-onset keratitis requiring intravitreal antibiotics. J Cataract Refract Surg. 2003;29(7):1370-1372.
36. Duker JS, Belmont JB. Late bacterial endophthalmitis following retinal detachment surgery. Retina. 1989;9(4):263-266.
37. Pathengay A, Karosekar S, Raju B, Sharma S, Das T. Microbiologic spectrum and susceptibility of isolates in scleral buckle infection in India. Am J Ophthalmol. 2004;138(4):663-664.
38. Recchia FM, Baumal CR, Sivalingam A, Kleiner R, Duker JS, Vrabec TR. Endophthalmitis after pediatric strabismus surgery. Arch Ophthalmol. 2000;118(7):939-944.
39. Proenca-Pina J, Ssi Yan Kai I, Bourcier T, Fabre M, Offret H, Labetoulle M. Fusarium keratitis and endophthalmitis associated with lens contact wear. Int Ophthalmol. 2010;30(1):103-107.
40. Lopez PF, Beldavs RA, al-Ghamdi S, Wilson LA, Wojno TH, Sternberg P Jr, et al. Pneumococcal endophthalmitis associated with nasolacrimal obstruction. Am J Ophthalmol. 1993;116(1):56-62.
41. Mino de Kaspar H, Shriver EM, Nguyen EV, et al. Risk factors for antibiotic-resistant conjunctival bacterial flora in patients undergoing intraocular surgery. Graefes Arch Clin Exp Ophthalmol. 2003;241(9):730-733.
42. Dortzbach RK, Woog JJ. Choice of procedure. Enucleation, evis-ceration, or prosthetic fitting over globes. Ophthalmology. 1985;92(9): 1249-1255.
43. Mino de Kaspar H, Grasbon T, Kampik A. Automated surgi-cal equipment requires routine disinfection of vacuum control manifold to prevent postoperative endophthalmitis. Ophthalmology. 2000;107(4):685-690.
44. Roy M, Chen JC, Miller M, Boyaner D, Kasner O, Edelstein E. Epidemic Bacillus endophthalmitis after cataract surgery I: Acute presentation and outcome. Ophthalmology. 1997;104(11):1768-1772.
45. Zaluski S, Clayman HM, Karsenti G, et al. Pseudomonas aeruginosa endophthalmitis caused by contamination of the internal fluid pathways of a phacoemulsifier. J Cataract Refract Surg. 1999;25(4):540-545.
46. Montan PG, Koranyi G, Setterquist HE, Stridh A, Philipson BT, Wiklund K. Endophthalmitis after cataract surgery: Risk factors relating to technique and events of the operation and patient history. A retrospec-tive case-control study. Ophthalmology. 1998;105(12):2171-2177.
47. Schmitz S, Dick HB, Krummenauer F, Pfeiffer N. Endophthalmitis in cataract surgery: Results of a German survey. Ophthalmology. 1999;106(10):1869-1877.
48. Gallenga PE, Mastropasqua L, Carpineto P, et al. In vitro Staphylococcus epidermidis growth in some viscoelastic substances containing sodium hyaluronate. Ophthalmologica. 1998;212(3):184-187.
49. Mastropasqua L, Piccolomini R, Carpineto P, et al. In vitro viability of external eye microbial flora in hydroxy-propyl-methylcellulose. Ophthalmologica. 1999;213(4):265-268.
50. Mamalis N, Kearsley L, Brinton E. Postoperative endophthalmitis. Curr Opin Ophthalmol. 2002;13(1):14-18.
51. Breitbach R, Spitznas M. Perioperative risk of infection in cataract surgery. Klin Monatsbl Augenheilkd. 1991;198(2):94-98.
52. Meredith TA, Trabelsi A, Miller MJ, Aguilar E, Wilson LA. Spon-taneous sterilization in experimental Staphylococcus epidermidis endophthalmitis. Invest Ophthalmol Vis Sci. 1990;31(1):181-186.
53. Kunimoto DY, Das T, Sharma S, et al. Microbiologic spectrum and susceptibility of isolates: Part I. Postoperative endophthalmitis. Endophthalmitis Research Group. Am J Ophthalmol. 1999;128(2): 240-242.
54. Moshfeghi DM, Kaiser PK, Scott IU, et al. Acute endophthalmi-tis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol. 2003;136(5):791-796.
55. Prophylaxis of postoperative endophthalmitis following cataract surgery: Results of the ESCRS multicenter study and identification of risk factors. J Cataract Refract Surg. 2007;33(6):978-988.
56. No authors listed. Microbiologic factors and visual outcome in the endophthalmitis vitrectomy study. Am J Ophthalmol. 1996;122(6): 830-846.
57. Mao LK, Flynn HW Jr, Miller D, Pflugfelder SC. Endophthalmitis caused by streptococcal species. Arch Ophthalmol. 1992;110(6): 798-801.
58. Miller JJ, Scott IU, Flynn HW Jr, Smiddy WE, Corey RP, Miller D. Endophthalmitis caused by Streptococcus pneumoniae. Am J Ophthalmol. 2004;138(2):231-236.
59. Soriano F, Perez-Trallero E, Pallares R, et al. Streptococcus pneu-moniae endophthalmitis: A study of 36 cases with special reference to antibiotic resistance and treatment options. Clin Microbiol Infect. 2006;12(6):519-526.
60. Pinna A, Sechi LA, Zanetti S, Delogu D, Carta F. Adherence of ocular isolates of staphylococcus epidermidis to ACRYSOF intraocular lenses. A scanning electron microscopy and molecular biology study. Ophthalmology. 2000;107(12):2162-2166.
61. Pinna A, Zanetti S, Sechi LA, Usai D, Falchi MP, Carta F. In vitro adherence of Staphylococcus epidermidis to polymethyl methacrylate and ACRYSOF intraocular lenses. Ophthalmology. 2000;107(6): 1042-1046.
62. Affeldt JC, Flynn HW Jr, Forster RK, Mandelbaum S, Clarkson JG, Jarus GD. Microbial endophthalmitis resulting from ocular trauma. Ophthalmology. 1987;94(4):407-413.
63. Brinton GS, Topping TM, Hyndiuk RA, Aaberg TM, Reeser FH, Abrams GW. Posttraumatic endophthalmitis. Arch Ophthalmol. 1984;102(4):547-550.
64. Kresloff MS, Castellarin AA, Zarbin MA. Endophthalmitis. Surv Ophthalmol. 1998;43(3):193-224.
65. Chaudhry IA, Shamsi FA, Al-Harthi E, Al-Theeb A, Elzaridi E, Riley FC. Incidence and visual outcome of endophthalmitis associated with intraocular foreign bodies. Graefes Arch Clin Exp Ophthalmol. 2008;246(2):181-186.
66. Ariyasu RG, Kumar S, LaBree LD, Wagner DG, Smith RE. Microorganisms cultured from the anterior chamber of ruptured globes at the time of repair. Am J Ophthalmol. 1995;119(2):181-188.
67. Rubsamen PE, Cousins SW, Martinez JA. Impact of cultures on management decisions following surgical repair of penetrating ocular trauma. Ophthalmic Surg Lasers. 1997;28(1):43-49.
68. Thompson JT, Parver LM, Enger CL, Mieler WF, Liggett PE. Infectious endophthalmitis after penetrating injuries with retained intra-ocular foreign bodies. National Eye Trauma System. Ophthalmology. 1993;100(10):1468-1474.
69. Thompson WS, Rubsamen PE, Flynn HW Jr, Schiffman J, Cousins SW. Endophthalmitis after penetrating trauma. Risk factors and visual acuity outcomes. Ophthalmology. 1995;102(11):1696-1701.
70. Zhang Y, Zhang M, Jiang C, Yao Y, Zhang K. Endophthalmitis following open globe Injury. Br J Ophthalmol. Epub ahead of print. 2009 Aug 18.
71. Hooi SH, Hooi ST. Open-globe injuries: The experience at Hospi-tal Sultanah Aminah, Johor Bahru. Med J Malaysia. 2003;58(3): 405-412.
72. Sabaci G, Bayer A, Mutlu FM, Karagul S, Yildirim E. Endophthalmitis after deadly-weapon-related open-globe injuries: Risk factors, value of prophylactic antibiotics, and visual outcomes. Am J Ophthalmol. 2002;133(1):62-69.
73. Schrader WF. Epidemiology of open globe eye injuries: Analysis of 1026 cases in 18 years. Klin Monbl Augenheilkd. 2004;221(8): 629-635.
74. Alfaro DV, Roth DB, Laughlin RM, Goyal M, Liggett PE. Paediat-ric post-traumatic endophthalmitis. Br J Ophthalmol. 1995;79(10): 888-891.
75. Verbraeken H, Rysselaere M. Post-traumatic endophthalmitis. Eur J Ophthalmol. 1994;4(1):1-5.
76. Williams DF, Mieler WF, Abrams GW, Lewis H. Results and prognostic factors in penetrating ocular injuries with retained intraocular foreign bodies. Ophthalmology. 1988;95(7):911-916.
77. Bohigian GM, Olk RJ. Factors associated with a poor visual result in endophthalmitis. Am J Ophthalmol. 1986;101(3):332-341.
78. Ness T, Pelz K. Endophthalmitis: Improvement of culture results. Ophthalmologe. 2000;97(1):33-37.
79. Chee SP, Jap A. Endogenous endophthalmitis. Curr Opin Ophthalmol. 2001;12(6):464-470.
80. Shrader SK, Band JD, Lauter CB, Murphy P. The clinical spectrum of endophthalmitis: Incidence, predisposing factors, and features influenc-ing outcome. J Infect Dis. 1990;162(1):115-120.
81. Brod RD, Flynn HW Jr, Clarkson JG, Pflugfelder SC, Culbertson WW, Miller D. Endogenous Candida endophthalmitis. Management without intravenous amphotericin B. Ophthalmology. 1990;97(5):666-672; discussion 672-674.
82. Nakayama F, Soloway RD, Nakama T, et al. Hepatolithiasis in East Asia. Retrospective study. Dig Dis Sci. 1986;31(1):21-26.
83. Wong JS, Chan TK, Lee HM, Chee SP. Endogenous bacterial endo-phthalmitis: An east Asian experience and a reappraisal of a severe ocular affliction. Ophthalmology. 2000;107(8):1483-1491.
84. Chen YJ, Kuo HK, Wu PC, et al. A 10-year comparison of endogenous endophthalmitis outcomes: An east Asian experience with Klebsiella pneumoniae infection. Retina. 2004;24(3):383-390.
85. Ness T, Pelz K, Hansen LL. Endogenous endophthalmitis: Micro-organisms, disposition and prognosis. Acta Ophthalmol Scand. 2007;85(8):852-856.
86. Sallam A, Lynn W, McCluskey P, Lightman S. Endogenous Candida endophthalmitis. Expert Rev Anti Infect Ther. 2006;4(4):675-685.
87. Chen YC, Chang SC, Luh KT, Hsieh WC. Stable susceptibility of Candida blood isolates to fluconazole despite increasing use during the past 10 years. J Antimicrob Chemother. 2003;52(1):71-77.
88. Kibbler CC, Seaton S, Barnes RA, et al. Management and outcome of bloodstream infections due to Candida species in England and Wales. J Hosp Infect. 2003;54(1):18-24.
89. Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ. Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: Report from the ARTEMIS Global Antifungal Sus-ceptibility Program, 2001. J Clin Microbiol. 2003;41(4):1440-1446.
90. Marangon FB, Miller D, Giaconi JA, Alfonso EC. In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens. Am J Ophthalmol. 2004;137(5):820-825.
91. Kostick DA, Foster RE, Lowder CY, Meyers SM, McHenry MC. Endogenous endophthalmitis caused by Candida albicans in a healthy woman. Am J Ophthalmol. 1992;113(5):593-595.
92. Brooks RG. Prospective study of Candida endophthalmitis in hos-pitalized patients with candidemia. Arch Intern Med. 1989;149(10): 2226-2228.
93. Krishna R, Amuh D, Lowder CY, Gordon SM, Adal KA, Hall G. Should all patients with candidaemia have an ophthalmic examination to rule out ocular candidiasis? Eye. 2000;14(Pt 1):30-34.
94. Feman SS, Nichols JC, Chung SM, Theobald TA. Endophthalmitis in patients with disseminated fungal disease. Trans Am Ophthalmol Soc. 2002; 100: 67-70; discussion 70-71.
95. Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: Epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis. 2003;37(5): 634-643.
96. Donahue SP, Greven CM, Zuravleff JJ, et al. Intraocular candidiasis in patients with candidemia. Clinical implications derived from a prospective multicenter study. Ophthalmology. 1994;101(7): 1302-1309.
97. Rodriguez-Adrian LJ, King RT, Tamayo-Derat LG, Miller JW, Garcia CA, Rex JH. Retinal lesions as clues to disseminated bacterial and candidal infections: Frequency, natural history, and etiology. Medicine (Baltimore). 2003;82(3):187-202.
98. Maguire JI. Postoperative endophthalmitis: Optimal management and the role and timing of vitrectomy surgery. Eye (Lond). 2008;22(10):1290-1300.
99. Wykoff CC, Flynn HW Jr, Miller D, Scott IU, Alfonso EC. Exogenous fungal endophthalmitis: Microbiology and clinical outcomes. Ophthalmology. 2008;115(9):1501-1507.
100. Jackson TL, Williamson TH. Amikacin retinal toxicity. Br J Ophthalmol. 1999;83(10):1199-1200.
101. Seawright AA, Bourke RD, Cooling RJ. Macula toxicity after intra-vitreal amikacin. Aust N Z J Ophthalmol. 1996;24(2):143-146.
102. Recchia FM, Busbee BG, Pearlman RB, Carvalho-Recchia CA, Ho AC. Changing trends in the microbiologic aspects of postcataract endophthalmitis. Arch Ophthalmol. 2005;123(3):341-346.
103. Bains HS, Weinberg DV, Feder RS, Noskin GA. Postoperative vancomycin-resistant Enterococcus faecium endophthalmitis. Arch Ophthalmol. 2007;125(9):1292-1293.
104. Esmaeli B, Holz ER, Ahmadi MA, Krathen RA, Raad II. Endogenous endophthalmitis secondary to vancomycin-resistant enterococciinfection. Retina. 2003;23(1):118-119.
105. Nucci C, Artini M, Pasmore M, Missiroli F, Costerton JW, Selan L. A microbiological and confocal microscopy study documenting a slime-producing Staphylococcus epidermidis isolated from a nylon corneal suture of a patient with antibiotic-resistant endophthalmitis. Graefes Arch Clin Exp Ophthalmol. 2005;243(9):951-954.
106. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med. 1999;340(7): 493-501.
107. Anand AR, Therese KL, Madhavan HN. Spectrum of aetiological agents of postoperative endophthalmitis and antibiotic susceptibility of bacterial isolates. Indian J Ophthalmol. 2000;48(2):123-128.
108. Callegan MC, Ramirez R, Kane ST, Cochran DC, Jensen H. Antibacterial activity of the fourth-generation fluoroquinolones gatifloxacin and moxifloxacin against ocular pathogens. Adv Ther. 2003;20(5): 246-252.
109. McCulley JP, Caudle D, Aronowicz JD, Shine WE. Fourth-generation fluoroquinolone penetration into the aqueous humor in humans. Ophthalmology. 2006;113(6):955-959.
110. Hariprasad SM, Blinder KJ, Shah GK, et al. Penetration pharma-cokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous. Arch Ophthalmol. 2005;123(1):39-44.
111. Gao H, Pennesi ME, Qiao X, et al. Intravitreal moxifloxacin: Retinal safety study with electroretinography and histopathology in animal models. Invest Ophthalmol Vis Sci. 2006;47(4):1606-1611.
112. Kernt M, Hirneiss C, Neubauer AS, Liegl RG, Eibl KH, Wolf A, et al. Intracameral moxifloxacin: A safe option for endophthalmitis prophylaxis? In vitro safety profile for intraocular application. Ophthalmologe. Epub ahead of print 2009 Sep 17.
113. Ermis SS, Cetinkaya Z, Kiyici H, Inan UU, Ozturk F. Effects of intravitreal moxifloxacin and dexamethasone in experimental Staphylococcus aureus endophthalmitis. Curr Eye Res. 2007;32(4):337-344.
114. Ermis SS, Cetinkaya Z, Kiyici H, Ozturk F. Treatment of Staphylococcus epidermidis endophthalmitis with intravitreal moxifloxacin in a rabbit model. Tohoku J Exp Med. 2005;205(3):223-229.
115. Kowalski RP, Dhaliwal DK, Karenchak LM, et al. Gatifloxacin and moxifloxacin: An in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol. 2003;136(3):500-505.
116. Kernt M, Neubauer AS, Liegl RG, et al. Intracameral moxifloxacin: In vitro safety on human ocular cells. Cornea. 2009;28(5):553-561.
117. Kernt M, Neubauer AS, Ulbig MW, Kampik A, Welge-Lussen U. In vitro safety of intravitreal moxifloxacin for endophthalmitis treatment. J Cataract Refract Surg. 2008;34(3):480-488.
118. Lott MN, Fuller JJ, Hancock HA, et al. Vitreal penetration of oral moxifloxacin in humans. Retina. 2008;28(3):473-476.
119. Yagci R, Oflu Y, Dincel A, et al. Penetration of second-, third-, and fourth-generation topical fluoroquinolone into aqueous and vitreous humour in a rabbit endophthalmitis model. Eye (Lond). 2007;21(7):990-994.
120. Iyer MN, He F, Wensel TG, Mieler WF, Benz MS, Holz ER. Intravitreal clearance of moxifloxacin. Trans Am Ophthalmol Soc. 2005;103:76-81; discussion 81-83.
121. Deramo VA, Lai JC, Fastenberg DM, Udell IJ. Acute endophthalmitis in eyes treated prophylactically with gatifloxacin and moxifloxacin. Am J Ophthalmol. 2006;142(5):721-725.
122. Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone resistance in bacterial keratitis: A 5-year review. Ophthalmology. 1999;106(7):1313-1318.
123. Kunimoto DY, Sharma S, Garg P, Rao GN. In vitro susceptibility of bacterial keratitis pathogens to ciprofloxacin. Emerging resistance. Ophthalmology. 1999;106(1):80-805.
124. Kowalski RP, Romanowski EG, Mah FS, Yates KA, Gordon YJ. Intracameral Vigamox (moxifloxacin 0.5%) is non-toxic and effective in preventing endophthalmitis in a rabbit model. Am J Ophthalmol. 2005;140(3):497-504.
125. Masket S. Preventing, diagnosing, and treating endophthalmitis. J Cataract Refract Surg. 1998;24(6):725-726.
126. Barza M, Doft B, Lynch E. Ocular penetration of ceftriaxone, ceftazidime, and vancomycin after subconjunctival injection in humans. Arch Ophthalmol. 1993;111(4):492-494.
127. Iyer MN, Han DP, Yun HJ, et al. Subconjunctival antibiotics for acute postcataract extraction endophthalmitis - is it necessary? Am J Ophthalmol. 2004;137(6):1120-1121.
128. Smiddy WE, Smiddy RJ, Ba'Arath B, et al. Subconjunctival antibiotics in the treatment of endophthalmitis managed without vitrectomy. Retina. 2005;25(6):751-758.
129. Das T, Jalali S, Gothwal VK, Sharma S, Naduvilath TJ. Intravitreal dexamethasone in exogenous bacterial endophthalmitis: Results of a prospective randomised study. Br J Ophthalmol. 1999;83(9): 1050-1055.
130. Gan IM, Ugahary LC, van Dissel JT, et al. Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: A prospective randomized trial. Graefes Arch Clin Exp Ophthalmol. 2005;243(12):1200-1205.
131. Hall EF, Scott GR, Musch DC, Zacks DN. Adjunctive intravitreal dexamethasone in the treatment of acute endophthalmitis following cataract surgery. Clin Ophthalmol. 2008;2(1):139-145.
132. Shah GK, Stein JD, Sharma S, Sivalingam A, et al. Visual outcomes following the use of intravitreal steroids in the treatment of postoperative endophthalmitis. Ophthalmology. 2000;107(3): 486-489.
133. Doft BH, Kelsey SF, Wisniewski SR. Additional procedures after the initial vitrectomy or tap-biopsy in the Endophthalmitis Vitrectomy Study. Ophthalmology. 1998;105(4):707-716.
134. Kuhn F, Gini G. Ten years after... are findings of the Endophthalmitis Vitrectomy Study still relevant today? Graefes Arch Clin Exp Ophthalmol. 2005;243(12):1197-1199.
135. Greenwald MJ, Wohl LG, Sell CH. Metastatic bacterial endophthalmitis: A contemporary reappraisal. Surv Ophthalmol. 1986;31(2): 81-101.
136. Jaeger EE, Carroll NM, Choudhury S, et al. Rapid detection and identification of Candida, Aspergillus, and Fusarium species in ocular samples using nested PCR. J Clin Microbiol. 2000;38(8): 2902-2908.
137. Lohmann CP, Linde HJ, Reischl U. Improved detection of microorganisms by polymerase chain reaction in delayed endophthalmitis after cataract surgery. Ophthalmology. 2000;107(6):1047-1051; discussion 1051-1052.
138. Okhravi N, Adamson P, Carroll N, et al. PCR-based evidence of bacterial involvement in eyes with suspected intraocular infection. Invest Ophthalmol Vis Sci. 2000;41(11):3474-3479.
139. Dunlop AA, Wright ED, Howlader SA, et al. Suppurative corneal ulceration in Bangladesh. A study of 142 cases examining the microbiological diagnosis, clinical and epidemiological features of bacterial and fungal keratitis. Aust NZ J Ophthalmol. 1994;22(2):105-110.
140. Polack FM, Kaufman HE, Newmark E. Keratomycosis. Medical and surgical treatment. Arch Ophthalmol. 1971;85(4):410-416.
141. Srinivasan M, Gonzales CA, George C, et al. Epidemiology and aetiological diagnosis of corneal ulceration in Madurai, south India. Br J Ophthalmol. 1997;81(11):965-971.
142. Thomas PA. Mycotic keratitis - an underestimated mycosis. J Med Vet Mycol. 1994;32(4):235-256.
143. Benz MS, Scott IU, Flynn HW Jr, Unonius N, Miller D. Endophthalmitis isolates and antibiotic sensitivities: A 6-year review of culture-proven cases. Am J Ophthalmol. 2004;137(1):38-42.
144. Keswani T, Ahuja V, Changulani M. Evaluation of outcome of various treatment methods for endogenous endophthalmitis. Indian J Med Sci. 2006;60(11):454-460.
145. Narang S, Gupta A, Gupta V, et al. Fungal endophthalmitis following cataract surgery: Clinical presentation, microbiological spectrum, and outcome. Am J Ophthalmol. 2001;132(5):609-617.
146. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis. 2004;38(2):161-189.
147. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(5):503-535.
148. Axelrod AJ, Peyman GA, Apple DJ. Toxicity of intravitreal injection of amphotericin B. Am J Ophthalmol. 1973;76(4):578-583.
149. Hariprasad SM, Mieler WF, Holz ER, et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol. 2004;122(1):42-47.
150. Herbrecht R. Voriconazole: Therapeutic review of a new azole antifungal. Expert Rev Anti Infect Ther. 2004;2(4):485-497.
151. Gao H, Pennesi ME, Shah K, et al. Intravitreal voriconazole: An electroretinographic and histopathologic study. Arch Ophthalmol. 2004;122(11):1687-1692.
152. Kramer M, Kramer MR, Blau H, Bishara J, Axer-Siegel R, Weinberger D. Intravitreal voriconazole for the treatment of endogenous Aspergillus endophthalmitis. Ophthalmology. 2006;113(7):1184-1186.
153. Kernt M, Kampik A. Intracameral voriconazole: In vitro safety for human ocular cells. Toxicology. 2009;258(2-3):84-93.
154. Kernt M, Neubauer AS, De Kaspar HM, Kampik A. Intravitreal voriconazole: In vitro safety-profile for fungal endophthalmitis. Retina. 2009;29(3):362-370.
155. Bunya VY, Hammersmith KM, Rapuano CJ, Ayres BD, Cohen EJ. Topical and oral voriconazole in the treatment of fungal keratitis. Am J Ophthalmol. 2007;143(1):151-153.
156. Creti A, Esposito V, Bocchetti M, et al. Voriconazole curative treatment for Acremonium species keratitis developed in a patient with concomitant Staphylococcus aureus corneal infection: A case report. In Vivo. 2006;20(1):169-171.
157. Freda R. Use of oral voriconazole as adjunctive treatment of severe cornea fungal infection: Case report. Arq Bras Oftalmol. 2006;69(3):431-434.
158. Ozbek Z, Kang S, Sivalingam J, Rapuano CJ, Cohen EJ, Hammersmith KM. Voriconazole in the management of Alternaria keratitis. Cornea. 2006;25(2):242-244.
159. Durand ML, Kim IK, D'Amico DJ, et al. Successful treatment of Fusarium endophthalmitis with voriconazole and Aspergillus endophthalmitis with voriconazole plus caspofungin. Am J Ophthalmol. 2005;140(3):552-554.
160. Nehemy MB, Vasconcelos-Santos DV, Torqueti-Costa L, Magalhaes EP. Chronic endophthalmitis due to verticillium species after cataract surgery treated (or managed) with pars plana vitrectomy and oral and intravitreal voriconazole. Retina. 2006;26(2):225-227.
161. Binder MI, Chua J, Kaiser PK, Procop GW, Isada CM. Endogenous endophthalmitis: An 18-year review of culture-positive cases at a tertiary care center. Medicine (Baltimore). 2003;82(2):97-105.
162. Agarwal MB, Rathi SA, Ratho N, Subramanian R. Caspofungin: Major breakthrough in treatment of systemic fungal infections. J Assoc Physicians India. 2006;54:943-948.
163. Theuretzbacher U. Pharmacokinetics/pharmacodynamics of echinocandins. Eur J Clin Microbiol Infect Dis. 2004;23(11): 805-812.
164. Breit SM, Hariprasad SM, Mieler WF, Shah GK, Mills MD, Grand MG. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am J Ophthalmol. 2005;139(1):135-140.
165. Cornely OA, Schmitz K, Aisenbrey S. The first echinocandin: Caspofungin. Mycoses. 2002;45 Suppl 3:56-60.
166. Sarria JC, Bradley JC, Habash R, Mitchell KT, Kimbrough RC, Vidal AM. Candida glabrata endophthalmitis treated successfully with caspofungin. Clin Infect Dis. 2005;40(5):e46-e48.
167. Gauthier GM, Nork TM, Prince R, Andes D. Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis. Clin Infect Dis. 2005;41(3):e27-e28.
168. Goldblum D, Fausch K, Frueh BE, Theurillat R, Thormann W, Zimmerli S. Ocular penetration of caspofungin in a rabbit uveitis model. Graefes Arch Clin Exp Ophthalmol. 2007;245(6):825-833.
169. Kernt M, Hirneiss C, Neubauer AS, et al. Intracameral moxifloxacin: A safe option for endophthalmitis prophylaxis? In vitro safety profile for intraocular application. Ophthalmologe. Epub ahead of print 2009 sep 17.
170. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol. 1998;36(10):2950-2956.
171. Klepser ME, Ernst EJ, Ernst ME, Messer SA, Pfaller MA. Evaluation of endpoints for antifungal susceptibility determinations with LY303366. Antimicrob Agents Chemother. 1998;42(6): 1387-1391.
172. Pfaller MA, Marco F, Messer SA, Jones RN. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis. 1998;30(4): 251-255.